Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interaction between fenofibrate and warfarin

K J Ascah1, G A Rock, P S Wells

  • 1Department of Medicine, University of Ottawa, Ontario, Canada.

The Annals of Pharmacotherapy
|July 29, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plasma Exchange for Acute Renal Failure of Myeloma-Logical, Yet Ineffective: Plasma Exchange When Myeloma Presents as Acute Renal Failure. A Randomized, Controlled Trial. Ann Int Medicine 143: 777-784, 2005.

Journal of the American Society of Nephrology : JASN·2023
Same author

Search for New Phenomena in Final States with Two Leptons and One or No b-Tagged Jets at sqrt[s]=13  TeV Using the ATLAS Detector.

Physical review letters·2021
Same author

Search for Displaced Leptons in sqrt[s]=13  TeV pp Collisions with the ATLAS Detector.

Physical review letters·2021
Same author

Longitudinal Flow Decorrelations in Xe+Xe Collisions at sqrt[s_{NN}]=5.44  TeV with the ATLAS Detector.

Physical review letters·2021
Same author

Search for Dark Matter Produced in Association with a Dark Higgs Boson Decaying into W^{±}W^{∓} or ZZ in Fully Hadronic Final States from sqrt[s]=13  TeV pp Collisions Recorded with the ATLAS Detector.

Physical review letters·2021
Same author

Medium-Induced Modification of Z-Tagged Charged Particle Yields in Pb+Pb Collisions at 5.02 TeV with the ATLAS Detector.

Physical review letters·2021
Same journal

Prolonged Response to Nivolumab in Metastatic Vulvar Carcinoma: Should Immunotherapy be Continued and for How Long? A Debatable Issue!

The Annals of pharmacotherapy·2026
Same journal

Stability of Ceftazidime-Avibactam: Changes in Regulatory Information and Implications for Preparation.

The Annals of pharmacotherapy·2026
Same journal

Impact of Early Dose Adjustment of Piperacillin/Tazobactam on Mortality in Critically Ill Patients With Acute Kidney Injury: A Retrospective Multicenter Cohort Study.

The Annals of pharmacotherapy·2026
Same journal

Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care.

The Annals of pharmacotherapy·2026
Same journal

Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated Systematic Review and Meta-Analysis of RCTs.

The Annals of pharmacotherapy·2026
Same journal

RSVpreF: A Vaccine for the Respiratory Syncytial Virus.

The Annals of pharmacotherapy·2026
See all related articles

Fenofibrate significantly potentiates warfarin's anticoagulant effect. Close monitoring of the international normalized ratio (INR) is crucial when these drugs are used together to prevent excessive anticoagulation.

Area of Science:

  • Pharmacology
  • Drug Interactions
  • Clinical Medicine

Background:

  • Warfarin is a widely used oral anticoagulant.
  • Fenofibrate is a common lipid-lowering agent.
  • Potential drug interactions require careful evaluation.

Observation:

  • Two patients experienced potentiation of warfarin's anticoagulant effect while taking fenofibrate.
  • Rechallenge confirmed a significant increase in the international normalized ratio (INR).
  • Decreased clotting factor concentrations correlated with elevated INR.

Findings:

  • A highly probable potentiating interaction between fenofibrate and warfarin was observed.
  • The mechanism may involve fenofibrate affecting coagulation factor synthesis, similar to clofibrate.

Related Experiment Videos

  • Exaggerated anticoagulant effects can occur within 5-10 days of initiating fenofibrate therapy.

    • Implications:

    • Increased use of lipid-lowering agents necessitates awareness of potential interactions with anticoagulants.
    • Serial INR monitoring (at least three times weekly) is strongly recommended when initiating fenofibrate in warfarin patients.
    • This interaction highlights the importance of vigilant patient monitoring in polypharmacy scenarios.